Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial

Abstract

The GD bi-weekly regimen is well tolerated and active as first line in anthracyclines-pretreated women with MBC. It appears as an interesting alternative compared to a 3-week schedule whenever hematological toxicity is the main clinical concern.

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

“…Murialdo et al [31] recently reported a phase II trial of biweekly docetaxel and gemcitabine regimen in HER2-negative and anthracycline-pretreated MBC, which showed that this schedule of administration is well tolerated and active as first line in anthracycline-pretreated women with MBC. Further investigation into phase III studies is required.…”